These findings suggest that IAPPO and autoantibodies against the peptide are implicated in AD-related events in an APOE4-dependent manner, potentially driven by an enhanced influx of toxic IAPPO from blood to brain due to a reduced clearance by IAPPO-Igs. This evidence concerns the gene CUBN and Alzheimer disease.